The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
暂无分享,去创建一个
D. Jewell | D P Jewell | A G Fraser | T R Orchard | A. Fraser | T. Orchard | Alan G. Fraser | Derek P. Jewell
[1] R. Vega,et al. Azathioprine in inflammatory bowel disease: An 8-year study and assessment of response predictors , 1998 .
[2] B. Levin,et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. , 1975, Gastroenterology.
[3] S. Rosewicz,et al. Retinoic acid receptor γ1 expression determines retinoid sensitivity in pancreatic carcinoma cells , 1998 .
[4] K. Mak,et al. Metabolism of alcohol by human gastric cells: relation to first-pass metabolism. , 1996, Gastroenterology.
[5] Sandborn Wj. Azathioprine: State of the Art in Inflammatory Bowel Disease , 1998 .
[6] G. Fick,et al. Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.
[7] J. Lennard-jones,et al. DOUBLE-BLIND WITHDRAWAL TRIAL OF AZATHIOPRINE AS MAINTENANCE TREATMENT FOR CROHN'S DISEASE , 1978, The Lancet.
[8] R. Modigliani,et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine , 1996, The Lancet.
[9] J. Lennard-jones,et al. Controlled trial of azathioprine in chronic ulcerative colitis. , 1982, British medical journal.
[10] B. Korelitz,et al. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. , 1994, The American journal of gastroenterology.
[11] B. Pasternack,et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.
[12] Ching-Hon Pui,et al. Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance , 1997, Annals of Internal Medicine.
[13] B. Kirschner,et al. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. , 1998, Gastroenterology.
[14] M. Kamm,et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. , 1993, Gut.
[15] D. Jewell,et al. Azathioprine in Ulcerative Colitis: Final Report on Controlled Therapeutic Trial , 1974, British medical journal.
[16] A. Axon,et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. , 1992, BMJ.
[17] C. Bodian,et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. , 1996, The American journal of gastroenterology.
[18] M. Gerig,et al. A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.
[19] G. Fick,et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. , 1995, Annals of internal medicine.
[20] M. Kamm,et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease , 1994, The Lancet.
[21] W. Sandborn. Azathioprine: state of the art in inflammatory bowel disease. , 1998, Scandinavian journal of gastroenterology. Supplement.
[22] S. Meltzer,et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.
[23] Williams,et al. Immunosuppressive therapy for ulcerative colitis: results of a nation‐wide survey among consultant physician members of the British Society of Gastroenterology , 1999, Alimentary pharmacology & therapeutics.